BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Athenagen Inc. Completes Merger With Zapaq, Inc.


8/14/2006 10:19:54 AM

SOUTH SAN FRANCISCO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Athenagen, Inc. said today that it has closed its previously announced merger with Zapaq, Inc. The combined privately held company is called Athenagen, with W. Scott Harkonen, M.D., as President and Chief Executive Officer and Robert McNeil, Ph.D., as Executive Chairman. The merger unites the companies' extensive research and development programs to create a leading neurovascular therapeutics pipeline. Terms of the merger were not disclosed.

Athenagen is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer's disease, AMD and cognitive disorders. The company has two fundamental technology platforms: (i) beta-secretase inhibitors for the treatment of Alzheimer's disease; and (ii) nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders. Athenagen currently has four product development programs based on these two technologies: ATG003, a topical (eye drop) anti-angiogenesis compound for neovascular AMD entering a Phase 1 study; GTS-21, an oral agonist of the alpha-7 nACh receptor pathway for cognition enhancement currently in a Phase 2 study; ATG002, a topical (gel) pro-angiogenesis compound for diabetic foot ulcers currently under an active IND and ready for Phase 1/2 study; and two clinical candidates from the beta-secretase inhibitor program approaching Phase 1 study for Alzheimer's disease in the first quarter of 2007. Athenagen has its headquarters in South San Francisco and has research operations in both South San Francisco and Oklahoma City. For more information: www.athenagen.com.

Athenagen, Inc.

CONTACT: W. Scott Harkonen, M.D., President and CEO of Athenagen, Inc.,+1-650-869-7600, or press@athenagen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES